Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Clorox Co (CLX) Price & Performance

Amgen, Inc.Trade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Clorox Co — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Clorox Co trades at $108.39 (market cap $13.09B). The key difference: Amgen, Inc. is far larger — about 17.1× Clorox Co's market cap, and Clorox Co pays the higher dividend (4.62%). Which is the better fit depends on your goals.

AMGNCLX
Market Cap
$224.14B$13.09B
Sector
HealthConsumer Staples
52-Week High
$417.20$127.16
52-Week Low
$271.18$86.12
Enterprise Value
$267.45B$18.47B
Dividend Yield
2.43%4.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.

Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.

Clorox Co

Clorox (CLX) trades at $105.69, down 1.87% on the day, with a mixed technical picture showing bullish moving averages but overbought RSI signals. Recent Q4 2026 earnings beat expectations with EPS of $1.66 versus $1.64 estimated, though revenue trends remain pressured by inflation and consumer value-seeking. The company increased its quarterly dividend to $1.25 per share, signaling confidence in cash flow stability.

Outlook is cautious amid margin pressures and competitive threats, with Wall Street largely neutral (69% hold rating). The consensus price target of $97.50 suggests limited upside from current levels, while debt-to-asset ratio rising to 66.4% in 2026 highlights balance sheet risks. Investment appeal hinges on successful cost management and category recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Clorox Co

With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.

Read more on CLX